RIGI and hepatocellular carcinoma: Regarding the antitumor effect of RIG-I, Liu et al. have demonstrated that downregulation of RIG-I in hepatocellular carcinoma is correlated with poor clinical outcome, while in vitro overexpression of RIG-I can enhance the interferon response to suppress proliferation of hepatocellular carcinoma [33].